Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05925920 · ClinicalTrials.gov registry record · Phase 1
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
A Phase 1 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Metabolics Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT05925920: Active Phase 1 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Metabolics Pharma.
NCT05925920 is a Phase 1 study of Obesity and Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Metabolics Pharma. The registered enrollment target is 49 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05925920, a Phase 1 study of Obesity and Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Metabolics Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes.
Primary Outcome
Treatment Emergent Adverse events (TEAEs) were collected from Day 1 (dosing visit ) through End of Study visit (Day 14 post-dose). TEAEs were defined as any AE with onset on or after the date of study drug administration. TEAEs were recorded by the investigator based on subject report, clinical observation, physical examination, vital signs, laboratory assessments, and ECG findings. Severity was graded per NCI CTCAE v5.0. Relatedness to study drug was assessed by the investigator. TEAEs of speci
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ENT-03
Study Locations (1)
California
- ProSciento - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2024-12-06 |
| Phase | Phase 1 |
What the registry record for NCT05925920 still lists
NCT05925920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05925920 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05925920 about?
NCT05925920 is a clinical study titled "Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes". Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes.
What is the current status of trial NCT05925920?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2023-06-13. Estimated completion is 2024-12-06.
What conditions does trial NCT05925920 study?
This clinical trial studies the following conditions: Obesity, Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT05925920?
The interventions under investigation include: Placebo (DRUG), ENT-03 (DRUG).
Who is sponsoring clinical trial NCT05925920?
This trial is sponsored by Metabolics Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05925920 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05925920's enrollment target sits among peer trials
49 731st of 1053 higher than 321 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI